Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Oct 27

PMID 36293289

Authors

Theresa Aliwarga

Jean C Dinh

Scott Heyward

Bhagwat Prasad

Sina A Gharib

Rozenn N Lemaitre

Nona Sotoodehnia

Rheem A Totah

Affiliations

Soon will be listed here.

Abstract

CYP2J2 is the main epoxygenase in the heart that is responsible for oxidizing arachidonic acid to -epoxyeicosatrienoic acids (EETs). Once formed, EETs can then be hydrolyzed by soluble epoxide hydrolase (sEH, encoded by ) or re-esterified back to the membrane. EETs have several cardioprotective properties and higher levels are usually associated with better cardiac outcomes/prognosis. This study investigates how cardiovascular disease (CVD) can influence total EET levels by altering protein expression and activity of enzymes involved in their biosynthesis and degradation. Diseased ventricular cardiac tissues were collected from patients receiving Left Ventricular Assist Device (LVAD) or heart transplants and compared to ventricular tissue from controls free of CVD. EETs, and enzymes involved in EETs biosynthesis and degradation, were measured using mass spectrometric assays. Terfenadine hydroxylation was used to probe CYP2J2 activity. Significantly higher - and -EET levels were observed in control cardiac tissue ( = 17) relative to diseased tissue ( = 24). Control cardiac tissue had higher CYP2J2 protein levels, which resulted in higher rate of terfenadine hydroxylation, compared to diseased cardiac tissues. In addition, levels of both NADPH-Cytochrome P450 oxidoreductase (POR) and sEH proteins were significantly higher in control versus diseased cardiac tissue. Overall, alterations in protein and activity of enzymes involved in the biosynthesis and degradation of EETs provide a mechanistic understanding for decreased EET levels in diseased tissues.

References

Yet S, Layne M, Liu X, Chen Y, Ith B, Sibinga N . Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J. 2003; 17(12):1759-61. DOI: 10.1096/fj.03-0187fje. View

Moessinger C, Kuerschner L, Spandl J, Shevchenko A, Thiele C . Human lysophosphatidylcholine acyltransferases 1 and 2 are located in lipid droplets where they catalyze the formation of phosphatidylcholine. J Biol Chem. 2011; 286(24):21330-9. PMC: 3122193. DOI: 10.1074/jbc.M110.202424. View

Estabrook R, Franklin M, Cohen B, Shigamatzu A, Hildebrandt A . Biochemical and genetic factors influencing drug metabolism. Influence of hepatic microsomal mixed function oxidation reactions on cellular metabolic control. Metabolism. 1971; 20(2):187-99. DOI: 10.1016/0026-0495(71)90091-6. View

Lenaz G . The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life. 2002; 52(3-5):159-64. DOI: 10.1080/15216540152845957. View

Akagi S, Kono N, Ariyama H, Shindou H, Shimizu T, Arai H . Lysophosphatidylcholine acyltransferase 1 protects against cytotoxicity induced by polyunsaturated fatty acids. FASEB J. 2016; 30(5):2027-39. DOI: 10.1096/fj.201500149. View

Evangelista E, Lemaitre R, Sotoodehnia N, Gharib S, Totah R . CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity. Drug Metab Dispos. 2018; 46(4):380-386. PMC: 5829540. DOI: 10.1124/dmd.117.078840. View

Sun N, Youle R, Finkel T . The Mitochondrial Basis of Aging. Mol Cell. 2016; 61(5):654-666. PMC: 4779179. DOI: 10.1016/j.molcel.2016.01.028. View

Wu S, Moomaw C, Tomer K, Falck J, Zeldin D . Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996; 271(7):3460-8. DOI: 10.1074/jbc.271.7.3460. View

Prasad B, Bhatt D, Johnson K, Chapa R, Chu X, Salphati L . Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. Drug Metab Dispos. 2018; 46(7):943-952. PMC: 5987995. DOI: 10.1124/dmd.118.080523. View

10.

Zhou J, Ahmad F, Parikh S, Hoffman N, Rajan S, Verma V . Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. Circ Res. 2016; 118(8):1208-22. PMC: 4843504. DOI: 10.1161/CIRCRESAHA.116.308544. View

11.

Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M . Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension. 2008; 51(5):1379-85. PMC: 4544761. DOI: 10.1161/HYPERTENSIONAHA.107.105395. View

12.

Goulitquer S, Dreano Y, Berthou F, Corcos L, Lucas D . Determination of epoxyeicosatrienoic acids in human red blood cells and plasma by GC/MS in the NICI mode. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 876(1):83-8. DOI: 10.1016/j.jchromb.2008.10.035. View

13.

Yet S, Tian R, Layne M, Wang Z, Maemura K, Solovyeva M . Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res. 2001; 89(2):168-73. DOI: 10.1161/hh1401.093314. View

14.

Karara A, Dishman E, Blair I, Falck J, Capdevila J . Endogenous epoxyeicosatrienoic acids. Cytochrome P-450 controlled stereoselectivity of the hepatic arachidonic acid epoxygenase. J Biol Chem. 1989; 264(33):19822-7. View

15.

Lin L, Wartmann M, Lin A, Knopf J, Seth A, Davis R . cPLA2 is phosphorylated and activated by MAP kinase. Cell. 1993; 72(2):269-78. DOI: 10.1016/0092-8674(93)90666-e. View

16.

Aliwarga T, Raccor B, Lemaitre R, Sotoodehnia N, Gharib S, Xu L . Enzymatic and free radical formation of cis- and trans- epoxyeicosatrienoic acids in vitro and in vivo. Free Radic Biol Med. 2017; 112:131-140. PMC: 5623104. DOI: 10.1016/j.freeradbiomed.2017.07.015. View

17.

Lee C, Neul D, Clouser-Roche A, Dalvie D, Wester M, Jiang Y . Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos. 2009; 38(2):347-56. DOI: 10.1124/dmd.109.030270. View

18.

Theken K, Schuck R, Edin M, Tran B, Ellis K, Bass A . Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis. 2012; 222(2):530-6. PMC: 3361525. DOI: 10.1016/j.atherosclerosis.2012.03.022. View

19.

Kolodgie F, Burke A, Skorija K, Ladich E, Kutys R, Makuria A . Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26(11):2523-9. DOI: 10.1161/01.ATV.0000244681.72738.bc. View

20.

Fang C, Gu J, Xie F, Behr M, Yang W, Abel E . Deletion of the NADPH-cytochrome P450 reductase gene in cardiomyocytes does not protect mice against doxorubicin-mediated acute cardiac toxicity. Drug Metab Dispos. 2008; 36(8):1722-8. PMC: 2575052. DOI: 10.1124/dmd.108.021881. View